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Ryan et al have recently written a useful article on managing dyslipidaemia for the 
primary prevention of cardiovascular disease1. They consider the evidence regarding the 
benefits and harms of statin medication and conclude that, “At present we have no way 
of knowing who will experience the benefits or harms of statin therapy before starting 
medication”. We would like to highlight to readers a couple of our papers which have 
addressed this question2. In 2010, we published a large population-based cohort study 
using the QResearch database (www.qresearch.org) to individualise the risks of statins 
in men and women in England. We also produced a web calculator 
www.qintervention.org which allows an individual calculate these risks. In 2018, we 
published an update to the QDiabetes-2018 algorithm which, for the first time, quantifies 
the risk of developing diabetes among patients prescribing statins, taking account of 
their other risk factors3. The web calculator can be found here www.qdiabetes.org/2018. 
Lastly, we would also like to highlight the publication of QRISK3 
https://qrisk.org/three/index.php last year in the BMJ4 which will replace QRISK2 later 
this year. 
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